Novo Loses Second Place in Danish Revenue Rankings to DSV
- DSV’s $15.9 billion Schenker purchase almost doubles revenue
- Takeover adds diversity to Danish economy dominated by pharma
This article is for subscribers only.
Denmark’s economy has become intertwined with Novo Nordisk A/S, famous for its fast-selling weight-loss treatments, but the pharma giant just got a bump down on the list of the Nordic country’s biggest revenue generators.
DSV A/S’s new acquisition, the $15.9 billion takeover of DB Schenker, will almost double the freight company’s sales, making it Denmark’s second-largest firm by that measure and pushing Novo down to third.